Moreover, HRGβ2 blockade is accompanied by a marked reduction in tumor formation, tumor size, and an absence of metastasis in vivo [11], thus confirming the ability of HRGβ2 to drive carcinogenesis independently of HER2. This evidence concerns the gene ERBB2 and neoplasm.